Vanguard Personalized Indexing Management LLC Sells 3,766 Shares of Intuitive Surgical, Inc. $ISRG

Vanguard Personalized Indexing Management LLC reduced its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 6.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 53,711 shares of the medical equipment provider’s stock after selling 3,766 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Intuitive Surgical were worth $24,029,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of ISRG. Tobam lifted its position in shares of Intuitive Surgical by 666.7% in the second quarter. Tobam now owns 46 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 40 shares in the last quarter. Kilter Group LLC acquired a new position in shares of Intuitive Surgical during the 2nd quarter worth about $27,000. Princeton Global Asset Management LLC bought a new position in shares of Intuitive Surgical in the 2nd quarter valued at about $30,000. Riggs Asset Managment Co. Inc. increased its position in shares of Intuitive Surgical by 84.2% in the second quarter. Riggs Asset Managment Co. Inc. now owns 70 shares of the medical equipment provider’s stock valued at $38,000 after acquiring an additional 32 shares during the last quarter. Finally, First Command Advisory Services Inc. raised its holdings in Intuitive Surgical by 3,750.0% during the second quarter. First Command Advisory Services Inc. now owns 77 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 75 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors.

Intuitive Surgical Trading Down 0.3%

ISRG opened at $523.99 on Monday. The company has a market cap of $187.84 billion, a P/E ratio of 66.41, a PEG ratio of 4.26 and a beta of 1.67. The company’s 50 day moving average is $562.32 and its 200-day moving average is $511.56. Intuitive Surgical, Inc. has a 1-year low of $425.00 and a 1-year high of $609.08.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 earnings per share for the quarter, beating analysts’ consensus estimates of $2.27 by $0.26. Intuitive Surgical had a net margin of 28.38% and a return on equity of 15.06%. The firm had revenue of $2.87 billion for the quarter, compared to analyst estimates of $2.72 billion. During the same quarter last year, the business posted $2.21 earnings per share. The company’s quarterly revenue was up 18.8% on a year-over-year basis. On average, equities analysts forecast that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Insider Transactions at Intuitive Surgical

In other news, EVP Henry L. Charlton sold 13,731 shares of Intuitive Surgical stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $580.00, for a total transaction of $7,963,980.00. Following the sale, the executive vice president directly owned 3,056 shares of the company’s stock, valued at approximately $1,772,480. This trade represents a 81.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Gary S. Guthart sold 22,806 shares of the company’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $570.89, for a total value of $13,019,717.34. Following the completion of the transaction, the insider directly owned 2,694 shares of the company’s stock, valued at $1,537,977.66. This represents a 89.44% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 55,714 shares of company stock valued at $31,617,799. 0.70% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

ISRG has been the subject of a number of analyst reports. Rothschild & Co Redburn raised their price target on Intuitive Surgical from $610.00 to $615.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Truist Financial upped their price target on shares of Intuitive Surgical from $620.00 to $650.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Jefferies Financial Group lifted their price objective on shares of Intuitive Surgical from $550.00 to $560.00 and gave the company a “hold” rating in a research report on Wednesday, October 22nd. Weiss Ratings reiterated a “hold (c+)” rating on shares of Intuitive Surgical in a research note on Monday, December 29th. Finally, Leerink Partners lifted their target price on Intuitive Surgical from $593.00 to $600.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 22nd. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $618.70.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.